Sorrento Therapeutics, Inc. and IGDRASOL Announce the Acquisition of Exclusive Distribution Rights to Cynviloq™ for the European Union PR...
Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment...
Sorrento Therapeutics, Inc. and IGDRASOL Announce Three Presentations on Cynviloq™ (IG-001; paclitaxel polymeric micelle) at the American...
Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL Transaction establishes a pipeline led by IGDRASOL's late clinical stage...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT...
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ...
Awarepoint, Leading RTLS Provider for Hospitals, Continues Staffing Up for Growth Stephen Zaniboni, formerly of XIFIN, Inc., joins as CFO and...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.